News

Despite hepatitis C (HCV) incidence rates increasing, adequate screening for the virus continues to be a pressing challenge for public health officials.

A study reported at IDWeek looked at this population and found gaps in testing.

Company plans to start recruiting for its REPREVE study this year.

The companies' initial focus will be around Assembly’s established areas of development including hepatitis B and D, as well as herpesviruses.

A study showed the Clostridioides difficile treatment remained effective after subsequent systemic antibiotic exposure.

A study presented at IDWeek details some of the shortfalls in utilization.

Excess death risks from GI diseases, above pre-pandemic patterns, were largest for C difficile colitis, followed by GI hemorrhage, ulcers, and colorectal cancer.

Contagion attended IDWeek, and here are some of the top stories we reported on while we were there. Continue to catch our coverage in the days to follow!

A number of factors has led to the increased incidence rates, but questions remain if the vector-borne disease's numbers are being captured accurately.

A Centers for Disease Control and Prevention (CDC) epidemiologist provides insights on a large study.

Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.

Heather Yun, MD, FACP, FIDS who is this year’s IDWeek Chair for the Infectious Diseases Society of America (IDSA) talks about the honor of the position, the collective effort to put together the conference, and offers insights on AMR during war, as well as new emerging infectious disease threats.

The findings may support further COVID-19 vaccination in children and reduce vaccine hesitancy.

A late-breaking abstract presented at IDWeek reports on the data around the Prefusion F Protein vaccine.

The findings emphasize the importance of reviewing all hepatitis B serology reports prior to switching HIV treatment.

Codagenix is reporting data at this year’s IDWeek for its live-attenuated vaccine candidate, CoviLiv.

The algorithm sought to address high rates of false-positive cultures, excessive antibiotic use, and unnecessary diagnostic procedures in an emergency department setting.

The combination antibiotic was equally effective against both monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus Complex infections.

The investigational treatment is being developed for this patient population.

Social determinants such as housing and transportation were strong predictors of patients receiving fecal microbiota transplants (FMT).

The monoclonal antibody demonstrated a significant impact on RSV-related hospitalizations regardless of infant characteristics.

Adding the oral therapy to standard of care helped reduce total days on oxygen for those hospitalized with COVID-19.

Earlier this year, cases of fungal meningitis were discovered at 2 surgical clinics in Matamoros, Mexico. The CDC offers an update on this deadly outbreak.

A study being presented at IDWeek 2023 demonstrated a 2-fold increase in HIV infections associated with barriers to treatment.

There is a lack of information and teaching going on with this significant, but "silent" organ.

Investigators explored the makeup of antibiotic resistant genes after administration of the live biotherapeutic product, Rebyota (fecal microbiota, Live-jslm), to see what differences would be discovered.

A New Drug Application (NDA) for ceftobiprole was accepted for 3 indications including S aureus bacteremia, days after phase 3 results were published.

Bradley Burnam, CEO of Turn Therapeutics, took his own personal medical experience with a severe skin infection and founded his company to address some of the unmet needs of wound care.

Hikers in Washington State experienced acute gastroenteritis along the Pacific Crest Trail.

In this week's infectious disease news, the Novavax COVID-19 booster gets authorized in the US; Moderna reports topline data on its influenza-COVID-19 combination vaccine; the differences between live biotherapeutic products and conventional FMTs; and the influence of alcohol on hepatitis C treatment.